17 June 2025 - Kye Pharmaceuticals today announced that Health Canada has approved its supplemental new drug submission regarding the recommended dosage of Fridapse (amifampridine) for adults to include that some patients may benefit from a total daily dose of 100 mg for the treatment of Lambert-Eaton myasthenic syndrome.

The direction that some patients may benefit from an increased maximum daily dose of up to 100 mg offers health care providers and patients greater flexibility in treatment regimens for the management of Lambert-Eaton myasthenic syndrome. The expanded indication includes paediatric dosing guidance for patients 6 years of age and older and offers paediatric neurologists a proven treatment option for children diagnosed with Lambert-Eaton myasthenic syndrome.

Read Kye Pharmaceuticals press release